Tumor lysis syndrome (TLS) is a serious, sometimes life-threatening oncologic emergency
caused by rapid and massive cellular lysis and subsequent release of tumor cell contents …

Correction of intravascular hypovolemia is a key component of the prevention and
management of acute kidney injury (AKI), but excessive fluid administration is associated …

Tumor lysis syndrome (TLS) is an oncologic emergency triggered by the rapid release of
intracellular material from lysing malignant cells. Most common in rapidly growing …

Acute kidney injury causes great morbidity and mortality in both the community and hospital
settings. Understanding the etiological factors and the pathophysiological principles …

Tumor lysis syndrome (TLS) is a common cause of acute kidney injury in patients with
malignancies, and it is a frequent condition for which the nephrologist is consulted in the …

Tumor lysis syndrome (TLS) is a potentially life-threatening condition that occurs in
oncologic and hematologic patients with large tumor burden, either due to cytotoxic therapy …

Tumor lysis syndrome (TLS) describes the clinical and laboratory sequelae that result from
the rapid release of intracellular contents of dying cancer cells. It is characterized by the …

Tumor lysis syndrome (TLS) is an oncologic emergency from the intracellular release of
material in lysing malignant cells. The earlier it is treated, the less likely it is to be harmful to …

Tumor lysis syndrome (TLS) is an acute, life-threatening disease among adults and children
that is associated with the initiation of cytoreductive therapy in the treatment of malignancy. A …

Patients with cancer represent a growing group among actual ICU admissions (up to 20%).
Due to their increased susceptibility to infectious and noninfectious complications related to …